Resource Centers

View More A-Fib Asthma Biosimilars Covid-19 Dermatology Eye Care Hemophilia HIV Liver Disease Multiple Sclerosis Post-Acute Care Prescription Digital Therapeutics Respiratory Conditions Sleep Disorders Substance Use Disorder Type II Inflammation

A-Fib Asthma Biosimilars Covid-19 Dermatology Eye Care Hemophilia HIV Liver Disease Multiple Sclerosis Post-Acute Care Prescription Digital Therapeutics Respiratory Conditions Sleep Disorders Substance Use Disorder Type II Inflammation

AMCP Annual Asembia’s 2022 Specialty Pharmacy Summit AMCP Nexus Examining Evolving Treatment Paradigms in the Hemophilia B Space Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven Conditions PBMI National Conference Unbranded Biologics: An Overview

AMCP Annual Asembia’s 2022 Specialty Pharmacy Summit AMCP Nexus Examining Evolving Treatment Paradigms in the Hemophilia B Space Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven Conditions PBMI National Conference Unbranded Biologics: An Overview

View More Business Strategy Chronic Disease Consumers Drug Costs Drug Pipeline Formulary Health Management Health/Disease Strategy Hospitals & Providers Industry Analysis Pharmacy Politics and Policy Practice Management Reimbursement Technology

Business Strategy Chronic Disease Consumers Drug Costs Drug Pipeline Formulary Health Management Health/Disease Strategy Hospitals & Providers Industry Analysis Pharmacy Politics and Policy Practice Management Reimbursement Technology

Expert Interviews

Medical World News

Population Health Perspectives

Expert Interviews K-Cast Medical World News Podcasts Population Health Perspectives

MHE Publication

Supplements And Featured Publications

MHE Publication Supplements And Featured Publications

Sponsored Content

PBM Leaders Sponsored Sponsored Content Surveys

Print Subscription

eNewsletter Print Subscription

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Informations

© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Resource CentersSee All >

A-Fib
Asthma
Biosimilars
Covid-19
Dermatology
Eye Care
Hemophilia
HIV
Liver Disease
Multiple Sclerosis
Post-Acute Care
Prescription Digital Therapeutics
Respiratory Conditions
Sleep Disorders
Substance Use Disorder
Type II Inflammation

Spotlight

AMCP Annual
Asembia’s 2022 Specialty Pharmacy Summit
AMCP Nexus
Examining Evolving Treatment Paradigms in the Hemophilia B Space
Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven Conditions
PBMI National Conference
Unbranded Biologics: An Overview

BusinessSee All >

Business Strategy
Chronic Disease
Consumers
Drug Costs
Drug Pipeline
Formulary
Health Management
Health/Disease Strategy
Hospitals & Providers
Industry Analysis
Pharmacy
Politics and Policy
Practice Management
Reimbursement
Technology

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Informations

© 2022 MJH Life Sciences^™ and Managed Healthcare Executive. All rights reserved.

Pleading for reason

February 1, 2002

Health plans demand outcomes-based evidence to support reference pricing for new drug therapies.